Ascentage Pharma announced that it has released updated clinical data of olverembatinib, a third-generation tyrosine kinase inhibitor, in patients with TKI-resistant succinate dehydrogenase -deficient gastrointestinal stromal tumor, in an oral report at the 60th American Society of Clinical Oncology Annual Meeting taking place in Chicago, IL.
